UNSPSC 51321712: Atorvastatin sodium

This classification denotes a hmg-coa reductase inhibitor with the molecular formula C33H34FN2O5.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DN43058TIV. European Medicines Agency schedules atorvastatin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35008. Most nations, for tariff and trade purposes, schedule atorvastatin sodium under HS 29339990 and SITC 51577. As of Q4 2014, ATORVASTATIN SODIUM remains US FDA's Preferred Term for this commodity.

Atorvastatin sodium bears US NLM identifiers UMLS ID C2698196 and NCI Concept Code C78676. SMILES: CC(C)C1C(C(C(N1CC[C@H](C[C@H](CC(=O)[O-])O)O)C2CCC(CC2)F)C3CCCCC3)C(=O)NC4CCCCC4.[NA+].

UNSPSC 51321712 Atorvastatin sodium is a Commodity code representing specific statin medications that state and local governments procure for emergency medical services, public health programs, and pharmacy benefit initiatives. State and local solicitations under this code track actual acquisitions of branded and generic cardiovascular medications for first-responder systems, multi-state cooperative purchasing alliances, and health and human services pharmacy programs. Issuing bodies include city fire and rescue departments, state health and human services commissions, and cooperative purchasing organizations spanning multiple states and local jurisdictions. The scope of work encompasses supplier relationships for pharmaceutical distribution, including compliance with FDA requirements, Drug Supply Chain Security Act (DSCSA) certification, current Good Manufacturing Practices (cGMP), OSHA Hazard Communication Standards for Safety Data Sheets, and contractual arrangements with authorized wholesalers or direct manufacturer agreements.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for Advanced Life Support Medications (response deadline April 8, 2026), requiring sealed bids for emergency cardiac and vasopressor agents supplied to Tampa Fire Rescue, with a Small Local Business Enterprise sheltered market designation and an estimated contract value of $40,000.00. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, signaling potential future formal procurement in that state. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities including Oregon, with proposal responses due March 26, 2026 and contract awards effective July 1, 2026; this procurement emphasizes price competitiveness (75 percent weight), compliance with wholesaler requirements, and multi-year contract terms with performance penalty structures.